Aclaris Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Aclaris Therapeutics

04/05/2024 01:18

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 7
for the period ending March 31 2024
    * The Wayne Pennsylvania-based  company is expected to
report a
45.9% decrease in revenue to $1.367 million from $2.53 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Aclaris Therapeutics Inc
is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $2.00​, above​ its last closing price
of $1.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.33       -0.34      -0.02     Beat    94.2
 Sep. 30 2023  -0.47       -0.48      -0.41     Beat    14.6
 Jun. 30 2023  -0.44       -0.45      -0.42     Beat    6.7​
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6
 ​​Jan.        -0.45       -0.45      -0.41     Beat    8
 1 0001                                                 
 Sep. 30 2022  -0.39       -0.40      -0.30     Beat    24.2​
 Jun. 30 2022  -0.36       -0.36      -0.31     Beat    13.5
 Jan. 1 0001   -0.40       -0.40      -0.31     Beat    23.1
 This summary was machine generated May 4 at 00:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)